Taspoglutide
- Generic Name
- Taspoglutide
- Drug Type
- Small Molecule
- Chemical Formula
- C152H232N40O45
- CAS Number
- 275371-94-3
- Unique Ingredient Identifier
- 2PHK27IP3B
- Background
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.
Tofogliflozin GLP-1 Analogue Combination Trial
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02537834
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT02227849
- Locations
- 🇯🇵
Reserch site, Kinki, Japan
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
Phase 3
Terminated
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 370
- Registration Number
- NCT01051011
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2118
- Registration Number
- NCT01018173
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 756
- Registration Number
- NCT00909597
A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT00823992
A Study of Taspoglutide in Type 2 Diabetic Patients
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00811460
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00809705
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1072
- Registration Number
- NCT00755287
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
Phase 3
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: Placebo (matching sitagliptin)Drug: Placebo (matching taspoglutide)
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 666
- Registration Number
- NCT00754988
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath